The Greater Cannabis Company, Inc. (GCAN)
| Market Cap | 482.78K |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -192,002 |
| Shares Out | 804.64M |
| EPS (ttm) | -0.00 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 10,000 |
| Open | 0.0006 |
| Previous Close | 0.0006 |
| Day's Range | 0.0006 - 0.0006 |
| 52-Week Range | 0.0003 - 0.0015 |
| Beta | 1.56 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About GCAN
The Greater Cannabis Company, Inc. engages in the development and commercialization of cannabinoid therapeutics. It offers an oral transmucosal patch platform, which provides loaded actives absorbed by the buccal mucosa into the body. The company has a license agreement with Shaare Zedek Scientific Ltd. that focuses on treatment of autism, schizophrenia, Parkinson's disease, Alzheimer's disease, and other neuropsychiatric disorders. The Greater Cannabis Company, Inc. was founded in 2014 and is based in Baltimore, Maryland. [Read more]
Full Company ProfileFinancial Performance
Financial StatementsNews
GCANRx Announces Completion of Preclinical Study for Neuropsychiatric Cannabinoid Therapy
BALTIMORE, MD, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Greater Cannabis Company, Inc. (“GCANRx” or the “Company”) (OTC: GCAN) a biopharmaceutical company pioneering development of next generation cannabinoi...
GCANRx Featured in American Journal of Endocannabinoid Medicine
BALTIMORE, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Greater Cannabis Company, Inc. (“GCANRx” or the “Company”) (OTC: GCAN) a publicly traded biopharmaceutical company pioneering development of next generati...
GCANRx Announces Approval of Phase II Clinical Trial to Treat Autism Related Spectrum Disorders
BALTIMORE, July 05, 2023 (GLOBE NEWSWIRE) -- Greater Cannabis Company, Inc. (“GCANRx” or the “Company”) (OTC: GCAN) a publicly traded biopharmaceutical company pioneering development of next generatio...
GCANRx Announces Submission of Phase 2 Clinical Trial Application to Treat Autism Related Spectrum Disorders
BALTIMORE, Oct. 07, 2022 (GLOBE NEWSWIRE) -- Greater Cannabis Company, Inc. (“GCANRx” or the “Company”) (OTC: GCAN) a biopharmaceutical company pioneering development of next generation cannabinoid th...
GCANRx Strategic Advisor Dr. Adi Aran to be Interviewed by Dr. Sanjay Gupta on CNN Cannabis Special
The 6 th Installment in the Award-winning Series by Dr. Sanjay Gupta will Air on Sunday, December 19 th at 9pm ET
GCANRx Appoints Renowned Cannabinoid Researcher Dr. Adi Aran as Strategic Advisor
Dr. Aran will be focused on furthering development of the therapeutic pipeline, advancing the clinical study program and supporting IP and regulatory strategies.
GCANRx Announces Initiation of Preclinical Study for Neuropsychiatric Cannabinoid Therapy
BALTIMORE, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Greater Cannabis Company, Inc. (“GCANRx” or the “Company”) (OTC: GCAN) a biopharmaceutical company pioneering development of next generation cannabinoid th...
GCANRx Signs Licensing Agreement with Shaare Zedek Scientific for Innovative Neuropsychiatric Cannabinoid Therapy
BALTIMORE, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Greater Cannabis Company, Inc. (“GCANRx” or the “Company”) (OTCQB: GCAN) a cannabis innovator specializing in the development of pharmaceutical and consume...
GCANRx Announces Collaboration with Renowned Cannabis Research Lab
BALTIMORE, March 16, 2021 (GLOBE NEWSWIRE) -- Greater Cannabis Company ( OTCQB: GCAN), an innovator in the development and commercialization of cannabinoid delivery systems and cannabinoid products i...
Greater Cannabis Company Announces Retirement of Remaining Convertible Debt
BALTIMORE, MD, Jan. 20, 2021 (GLOBE NEWSWIRE) -- The Greater Cannabis Company (GCAN), an innovator in the development and commercialization of cannabinoid delivery systems and cannabinoid products tod...